scholarly journals In vitro antimicrobial susceptibility study in clinical isolates of Streptococci and Enterococci

2011 ◽  
Vol 5 (12) ◽  
pp. 1374-1378 ◽  
Author(s):  
Patel H ◽  
Shah A ◽  
Mistry M ◽  
Ch S ◽  
a
Keyword(s):  
Antimicrobial Susceptibility ◽  
Clinical Isolates ◽  
Susceptibility Study

scholarly journals In vitro antimicrobial susceptibility in clinical isolates of Enterococcus species

2003 ◽  
Vol 45 (2) ◽  
Author(s):  
Ernesto Calderón-Jaimes ◽  
José Luis Arredondo-García ◽  
Felipe Aguilar-Ituarte ◽  
Pilar García-Roca
Keyword(s):  
Antimicrobial Susceptibility ◽  
Clinical Isolates ◽  
Enterococcus Species

In vitro antimicrobial susceptibility of equine clinical isolates from France, 2006–2016

2019 ◽  
Vol 19 ◽  
pp. 144-153 ◽  
Author(s):  
Rachel Duchesne ◽  
Sophie Castagnet ◽  
Karine Maillard ◽  
Sandrine Petry ◽  
Vincent Cattoir ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Clinical Isolates

scholarly journals Feasibility and potential significance of rapid in vitro qualitative phenotypic antimicrobial susceptibility testing of gram-negative bacilli with the ProMax system

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0249203
Author(s):  
Jade Chen ◽  
Michael Tomasek ◽  
Amorina Cruz ◽  
Matthew L. Faron ◽  
Dakai Liu ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Pathogenic Bacteria ◽  
Susceptibility Testing ◽  
Klebsiella Oxytoca ◽  
Antimicrobial Susceptibility Testing ◽  
Clinical Isolates ◽  
Clinical Samples ◽  
Automation System ◽  
Gram Negative

The emergence and evolution of antibiotic resistance has been accelerated due to the widespread use of antibiotics and a lack of timely diagnostic tests that guide therapeutic treatment with adequate sensitivity, specificity, and antimicrobial susceptibility testing (AST) accuracy. Automated AST instruments are extensively used in clinical microbiology labs and provide a streamlined workflow, simplifying susceptibility testing for pathogenic bacteria isolated from clinical samples. Although currently used commercial systems such as the Vitek2 and BD Phoenix can deliver results in substantially less time than conventional methods, their dependence on traditional AST inoculum concentrations and optical detection limit their speed somewhat. Herein, we describe the GeneFluidics ProMax lab automation system intended for a rapid 3.5-hour molecular AST from clinical isolates. The detection method described utilizes a higher starting inoculum concentration and automated molecular quantification of species-specific 16S rRNA through the use of an electrochemical sensor to assess microbiological responses to antibiotic exposure. A panel of clinical isolates consisting of species of gram-negative rods from the CDC AR bank and two hospitals, New York-Presbyterian Queens and Medical College of Wisconsin, were evaluated against ciprofloxacin, gentamicin, and meropenem in a series of reproducibility and clinical studies. The categorical agreement and reproducibility for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, and Pseudomonas aeruginosa were 100% and 100% for ciprofloxacin, 98.7% and 100% for gentamicin and 98.5% and 98.5% for meropenem, respectively.

scholarly journals In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi

2018 ◽  
Vol 62 (7) ◽  
pp. e00419-18 ◽  
Author(s):  
Joris Koetsveld ◽  
Annemijn Manger ◽  
Dieuwertje Hoornstra ◽  
Ronald O. Draga ◽  
Anneke Oei ◽  
...  
Keyword(s):  
Antimicrobial Susceptibility ◽  
Fetal Calf Serum ◽  
Calf Serum ◽  
Dark Field ◽  
Clinical Isolates ◽  
Borrelia Miyamotoi ◽  
Content Type ◽  
Dark Field Microscopy ◽  
Made In

ABSTRACT Borrelia miyamotoi is an emerging relapsing fever (RF) Borrelia species that is reported to cause human disease in regions in which Lyme borreliosis is endemic. We recently showed that B. miyamotoi tick isolates are resistant to amoxicillin in vitro; however, clinical isolates have not been studied. Therefore, our aim was to show the antimicrobial susceptibility of recently obtained clinical isolates of B. miyamotoi. A dilution series of various antibiotics was made in modified Kelly-Pettenkofer medium with 10% fetal calf serum. The susceptibilities of different B. miyamotoi clinical, B. miyamotoi tick, RF Borrelia, and Borrelia burgdorferi sensu lato isolates were tested by measuring MICs through colorimetric changes and by counting motile spirochetes by dark-field microscopy after 72 h of incubation. The ceftriaxone and azithromycin MIC ranges of the six B. miyamotoi clinical isolates tested were 0.03 to 0.06 mg/liter and 0.0016 to 0.0032 mg/liter, respectively. These values are similar to MICs for RF Borrelia strains and B. miyamotoi tick isolates. All tested RF Borrelia strains were susceptible to doxycycline (microscopic MIC range, 0.0625 to 0.25 mg/liter). In contrast to the MICs of the tested B. burgdorferi sensu lato strains and in line with our previous findings, the amoxicillin MICs (range, 8 to 32 mg/liter) of all RF Borrelia strains, including B. miyamotoi clinical isolates, were above the clinical breakpoint for resistance (≤4 mg/liter). Clinical isolates of B. miyamotoi are highly susceptible to doxycycline, azithromycin, and ceftriaxone in vitro. Interestingly, as described previously for tick isolates, amoxicillin shows poor in vitro activity against B. miyamotoi clinical isolates.

scholarly journals Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar

2019 ◽  
Vol 74 (12) ◽  
pp. 3497-3504 ◽  
Author(s):  
Mazen A Sid Ahmed ◽  
Hamad Abdel Hadi ◽  
Abubaker A I Hassan ◽  
Sulieman Abu Jarir ◽  
Muna A Al-Maslamani ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Public Hospitals ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Mechanisms Of Resistance ◽  
Test Strips

Abstract Objectives To investigate the in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against clinical isolates of MDR Pseudomonas aeruginosa from Qatar, as well as the mechanisms of resistance. Methods MDR P. aeruginosa isolated between October 2014 and September 2015 from all public hospitals in Qatar were included. The BD PhoenixTM system was used for identification and initial antimicrobial susceptibility testing, while Liofilchem MIC Test Strips (Liofilchem, Roseto degli Abruzzi, Italy) were used for confirmation of ceftazidime/avibactam and ceftolozane/tazobactam susceptibility. Ten ceftazidime/avibactam- and/or ceftolozane/tazobactam-resistant isolates were randomly selected for WGS. Results A total of 205 MDR P. aeruginosa isolates were included. Of these, 141 (68.8%) were susceptible to ceftazidime/avibactam, 129 (62.9%) were susceptible to ceftolozane/tazobactam, 121 (59.0%) were susceptible to both and 56 (27.3%) were susceptible to neither. Twenty (9.8%) isolates were susceptible to ceftazidime/avibactam but not to ceftolozane/tazobactam and only 8 (3.9%) were susceptible to ceftolozane/tazobactam but not to ceftazidime/avibactam. Less than 50% of XDR isolates were susceptible to ceftazidime/avibactam or ceftolozane/tazobactam. The 10 sequenced isolates belonged to six different STs and all produced AmpC and OXA enzymes; 5 (50%) produced ESBL and 4 (40%) produced VIM enzymes. Conclusions MDR P. aeruginosa susceptibility rates to ceftazidime/avibactam and ceftolozane/tazobactam were higher than those to all existing antipseudomonal agents, except colistin, but were less than 50% in extremely resistant isolates. Non-susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam was largely due to the production of ESBL and VIM enzymes. Ceftazidime/avibactam and ceftolozane/tazobactam are possible options for some patients with MDR P. aeruginosa in Qatar.

In vitro antimicrobial susceptibility of Mycoplasma bovis clinical isolates recovered from bison (Bison bison)

2016 ◽  
Vol 62 (3) ◽  
pp. 272-278 ◽  
Author(s):  
Muhammad Suleman ◽  
Tracy Prysliak ◽  
Claire Windeyer ◽  
Jose Perez-Casal
Keyword(s):  
Antimicrobial Susceptibility ◽  
Inhibitory Concentration ◽  
Bison Bison ◽  
Clinical Isolates ◽  
Economic Losses ◽  
Mycoplasma Bovis ◽  
Therapeutic Regime ◽  
Laboratory Reference ◽  
First Time

Mycoplasma bovis is a pathogen globally affecting cattle and bison herds, causing pneumonia, arthritis, mastitis, abortions, and other symptoms, leading to huge economic losses. Many studies have been done regarding the antimicrobial susceptibility of M. bovis isolated from cattle, but no such study is available for isolates recovered from bison. For the first time, in vitro susceptibilities of 40 M. bovis clinical isolates collected from bison herds in Canada are reported here. Minimal inhibitory concentration (MIC) values were determined using Sensititre® plates. The most effective MIC50 and MIC90 were for spectinomycin (1 and >64 μg/mL), tiamulin (1 and >32 μg/mL), and tulathromycin (16 and 64 μg/mL), whereas tetracyclines, fluoroquinolones, and florfenicol failed to inhibit growth of M. bovis bison isolates. Isolates were nonsusceptible to tetracyclines (100%), fluoroquinolones (97.5%), and tilmicosin (100%), whereas the highest susceptibility of bison clinical isolates was seen with spectinomycin (95%) and tulathromycin (67.5%). Two lung isolates (Mb283 and 348) were found resistant to both spectinomycin and tulathromycin. These results show a marked difference in antimicrobial susceptibility of bison isolates as compared with previously reported and laboratory reference cattle isolates, emphasizing the necessity of testing antimicrobial susceptibility of M. bovis bison isolates and to generate better therapeutic regime for improved recovery chances for infected bison herds across North America.

Sign in / Sign up

Export Citation Format

Share Document